AstraZeneca PLC American Depositary Shares (AZN)
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing
JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in global pharma. The bank says a wave of clinical readouts (and a high likelihood of success) positions AstraZeneca to benefit disproportionately as investors shift their attention away from US drug-pricing fears and back towards innovation.
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.
AstraZeneca to invest $2 billion as part of US manufacturing push
AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030.
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found.
AstraZeneca leans on its pipeline as $80bn revenue target comes into view
It is not every day that a company makes a habit of turning in positive clinical results at a pace that would make even the most seasoned drug developer blink. Yet AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has managed just that this year, and Shore Capital thinks the torrent of data is enough to justify a fresh uplift to forecasts, even if the real strategic test lies a little further down the road.
